Targeting cellular energy production in neurological disorders.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Energy dysregulation and oxidative stress are central to the pathophysiology of many neurological disorders.
• These conditions often share a common pathway leading to cell death (necrosis or apoptosis).
• Targeting bioenergetic defects offers a promising neuroprotective strategy.

Purpose of the Study:

• To review the biological functions of key compounds with neuroprotective potential.
• To discuss the therapeutic utility of these compounds in animal models and human neurological diseases.
• To focus on the applications of creatine monohydrate and coenzyme Q10.

Main Methods:

• Literature review of existing studies on neuroprotective compounds.
• Analysis of biological functions and mechanisms of action.
• Evaluation of evidence from animal models and human clinical trials.

Main Results:

• Creatine monohydrate and coenzyme Q10 demonstrate significant neuroprotection against ischemia, trauma, oxidative damage, and neurotoxins.
• Other agents like alpha-lipoic acid, beta-OH-beta-methylbutyrate, riboflavin, and nicotinamide improve metabolic parameters in brain and muscle.
• These compounds show potential in treating amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, Friedreich's ataxia, and mitochondrial cytopathies.

Conclusions:

• Compounds targeting energy metabolism and oxidative stress are vital for neuroprotection.
• Creatine monohydrate and coenzyme Q10 are particularly promising for treating a range of neurological and neuromuscular diseases.
• Further research into these agents could lead to novel therapeutic strategies for neurodegenerative conditions.